No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 343,329 | 371,348 | 383,811 | 370,537 | 268,861 | 272,239 | 275,329 | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 10,880 | 14,032 | 19,385 | -2,546 | 10,257 | 6,905 | 20,162 | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in South Korea, Ilyang Pharmaceutical Co.,Ltd operates as a significant enterprise within the pharmaceutical sector. The company offers an extensive array of medicinal products designed to address diverse health concerns, including treatments for cancer, circulatory ailments, endocrine and metabolic disorders, specific Cheonjiyang offerings, female hormone regulation, urinary tract issues, ophthalmological conditions, and liver diseases. Its portfolio further extends to digestive and respiratory system therapies, dermatological solutions, anti-inflammatory pain relievers, and neurological medications, alongside nutrient infusions, antibiotics, antifungal agents, insecticides, and vaccines. Beyond pharmaceuticals, Ilyang Pharmaceutical diversifies its product lines to include consumer health goods such as health drinks, daily food items, nutritional supplements, health foods, cosmetics, and various beverages. Moreover, it is a manufacturer of crucial pharmaceutical raw materials, producing a wide range of aluminum and magnesium compounds like aluminum hydroxide gel, magnesium hydroxide, hydrotalcite, magaldrate, and others. Established in 1946 and headquartered in Yongin, South Korea, the company, initially known as Il-Yang Pharm. Ind. Co. before its name change in May 1991, also exports its products to approximately 14 countries globally.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ilyang Pharmaceutical Co.,Ltd (007575.KS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Based in South Korea, Ilyang Pharmaceutical Co.,Ltd operates as a significant enterprise within the pharmaceutical sector. The company offers an extensive array of medicinal products designed to address diverse health concerns, including treatments for cancer, circulatory ailments, endocrine and metabolic disorders, specific Cheonjiyang offerings, female hormone regulation, urinary tract issues, ophthalmological conditions, and liver diseases. Its portfolio further extends to digestive and respiratory system therapies, dermatological solutions, anti-inflammatory pain relievers, and neurological medications, alongside nutrient infusions, antibiotics, antifungal agents, insecticides, and vaccines. Beyond pharmaceuticals, Ilyang Pharmaceutical diversifies its product lines to include consumer health goods such as health drinks, daily food items, nutritional supplements, health foods, cosmetics, and various beverages. Moreover, it is a manufacturer of crucial pharmaceutical raw materials, producing a wide range of aluminum and magnesium compounds like aluminum hydroxide gel, magnesium hydroxide, hydrotalcite, magaldrate, and others. Established in 1946 and headquartered in Yongin, South Korea, the company, initially known as Il-Yang Pharm. Ind. Co. before its name change in May 1991, also exports its products to approximately 14 countries globally.